Abstract
Crohn's disease (CD) is a chronic, progressive inflammatory disease with complications that impact the well-being of patients. The therapeutic advances achieved in recent decades, especially through the advent of biological therapy, have allowed for a transformation in the approach and management of CD, thereby modifying the course of this disease. However, a significant number of patients do not experience a satisfactory response to these drugs or lose it during the course of the disease. In this scenario, a viable alternative is to switch medications. Upadacitinib, a novel Janus kinase inhibitor, has emerged as a promising strategy for the management of CD. We presented two cases of patients with CD refractory to conventional therapy and biological therapy, who responded successfully to treatment with upadacitinib.
Translated title of the contribution | Utilization of Upadacitinib in the treatment of Crohn's disease: a report on two clinical cases |
---|---|
Original language | Spanish |
Pages (from-to) | 162-166 |
Number of pages | 5 |
Journal | Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru |
Volume | 44 |
Issue number | 2 |
State | Published - 1 Apr 2024 |